Acquisition History / Novo Nordisk A/S / Akero Therapeutics, Inc.
Novo Nordisk A/S Acquires Akero Therapeutics, Inc.
Announced October 9, 2025 — $4.70B
What happened
Akero Therapeutics is a clinical-stage company developing treatments for serious metabolic diseases. It agreed on October 9, 2025 to be acquired by Novo Nordisk for up to $5.2B in cash; the upfront portion represents an equity value of about $4.7B with the balance via a contingent value payment.
- Acquirer
- Novo Nordisk A/S
- Target
- Akero Therapeutics, Inc.
- Announced
- October 9, 2025
- Price
- $4.70B
- Industry
- MASH liver disease biotechnology
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did Novo Nordisk A/S acquire Akero Therapeutics, Inc.?
Novo Nordisk A/S acquired Akero Therapeutics, Inc. on October 9, 2025. This was Novo Nordisk A/S's 1st publicly tracked acquisition out of 1 we have on record.
How much did Novo Nordisk A/S pay for Akero Therapeutics, Inc.?
Novo Nordisk A/S paid $4.70B for Akero Therapeutics, Inc..
What does Akero Therapeutics, Inc. do?
Akero Therapeutics is a clinical-stage company developing treatments for serious metabolic diseases. It agreed on October 9, 2025 to be acquired by Novo Nordisk for up to $5.2B in cash; the upfront portion represents an equity value of about $4.7B with the balance via a contingent value payment.
What other MASH liver disease biotechnology companies has Novo Nordisk A/S acquired?
Akero Therapeutics, Inc. is Novo Nordisk A/S's only publicly tracked acquisition in MASH liver disease biotechnology so far.